Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess in vitro aggregation in patients with atrial...

Full description

Bibliographic Details
Main Authors: Juraj Sokol MD, PhD, Frantisek Nehaj MD, Jela Ivankova RNDr, Michal Mokan MD, PhD, Lenka Lisa MD, PhD, Jana Zolkova RNDr, Lubica Vadelova RNDr, Marian Mokan Prof, MD, DSc, FRCP Edin, Jan Stasko Prof, MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2020-10-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/1076029620948585

Internet

https://doi.org/10.1177/1076029620948585

Similar Items